HeartBeam Announces Senior Leadership Change
March 08 2023 - 8:31AM
Business Wire
Robert Eno Assumes Duties of Chief Business
Officer
Jon Hunt to Remain Strategic Advisor &
Consultant to HeartBeam
HeartBeam, Inc. (NASDAQ: BEAT), a
cardiac technology company that has developed the first and only
3D-vector electrocardiogram (VECG) platform for heart attack
detection anytime, anywhere, has announced a senior leadership
change ahead of key milestones in 2023 including FDA clearance for
the HeartBeam AIMI™ system and FDA submission of the HeartBeam
AIMIGo™ 3D vector ECG first generation product. HeartBeam President
Robert Eno will be assuming the duties and responsibilities of
Executive Vice President and Chief Business Officer Jon Hunt,
Ph.D., who will be stepping down from his current position and
transitioning to the role of strategic advisor and consultant for
the Company, effective March 15, 2023.
During his tenure, Dr. Hunt has made significant contributions
to HeartBeam’s business efforts, leading numerous initiatives and
introductions with partner manufacturing and technology companies
and health systems providers.
As a consultant, Dr. Hunt will remain involved in the Company's
business strategy and outreach to the medical community and sharing
his wealth of knowledge and experience to help guide HeartBeam’s
commercialization. His expertise and insights from over 34 years’
experience in the medical device industry will continue to support
the product launch timeline for the HeartBeam AIMIGo 12-Lead 3D
vector electrocardiogram (VECG) Device and HeartBeam AIMI
system.
“Jon has made numerous critical contributions to HeartBeam by
leading our planning efforts for market introductions of our
products,” said Branislav Vajdic, Ph.D., HeartBeam CEO and Founder.
“We understand his desire for a change of pace and a better
work-life-balance, and we are excited that Jon will, as a key
consultant, stay close to our strategic discussions and decisions.
His dedication and commitment to HeartBeam have been greatly
appreciated, and he will be missed in his current role. On behalf
of the entire team at HeartBeam, we thank Jon for his outstanding
service and leadership, and look forward to his expertise and
insights in a consultancy role.”
Dr. Hunt added, “It has been a privilege to serve as CBO of
HeartBeam, and I am incredibly proud of the rapid pace of our
product timeline and our team’s ability to scale our
commercialization path. After almost four decades in the
cardiovascular medical device industry, I want to spend more time
focusing on my family in the UK and US. I look forward to
continuing to work with the team as a consultant, focusing on
business strategy as the Company brings this breakthrough
technology to market for high-risk cardiac patients.”
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a cardiac technology company
that has developed the first and only 3D-vector ECG platform for
heart attack detection anytime, anywhere. By applying a suite of
proprietary algorithms to simplify vector electrocardiography
(VECG), the HeartBeam platform enables patients and their
clinicians to determine if symptoms are due to a heart attack,
quickly and easily, so care can be expedited, if required.
HeartBeam has two patented products in development. HeartBeam AIMI™
is software for acute care settings that provides a 3D comparison
of baseline and symptomatic 12-lead ECG to more accurately identify
a heart attack. HeartBeam AIMIGo™ is the first and only credit
card-sized 12-lead output ECG device coupled with a smart phone app
and cloud-based diagnostic software system to facilitate remote
heart attack detection. HeartBeam AIMI and AIMIGo have not yet been
cleared by the US Food and Drug Administration (FDA) for marketing
in the USA or other geographies. For more information, visit
HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical
fact are "forward-looking statements." While management has based
any forward-looking statements included in this release on its
current expectations, the information on which such expectations
were based may change. Forward-looking statements involve inherent
risks and uncertainties which could cause actual results to differ
materially from those in the forward-looking statements, as a
result of various factors including those risks and uncertainties
described in the Risk Factors and in Management’s Discussion and
Analysis of Financial Condition and Results of Operations sections
of our in our Forms 10-K, 10-Q and other reports filed with the SEC
and available at www.sec.gov. We urge you to consider those risks
and uncertainties in evaluating our forward-looking statements. We
caution readers not to place undue reliance upon any such
forward-looking statements, which speak only as of the date made.
Except as otherwise required by the federal securities laws, we
disclaim any obligation or undertaking to publicly release any
updates or revisions to any forward-looking statement contained
herein (or elsewhere) to reflect any change in our expectations
with regard thereto or any change in events, conditions or
circumstances on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230307005521/en/
Investor Relations Contact: Chris Tyson Executive Vice
President MZ North America Direct: 949-491-8235 BEAT@mzgroup.us
www.mzgroup.us
Media Contact:media@heartbeam.com
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From May 2024 to Jun 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jun 2023 to Jun 2024